Literature DB >> 26014293

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Robert H I Andtbacka1, Howard L Kaufman2, Frances Collichio1, Thomas Amatruda1, Neil Senzer1, Jason Chesney1, Keith A Delman1, Lynn E Spitler1, Igor Puzanov1, Sanjiv S Agarwala1, Mohammed Milhem1, Lee Cranmer1, Brendan Curti1, Karl Lewis1, Merrick Ross1, Troy Guthrie1, Gerald P Linette1, Gregory A Daniels1, Kevin Harrington1, Mark R Middleton1, Wilson H Miller1, Jonathan S Zager1, Yining Ye1, Bin Yao1, Ai Li1, Susan Doleman1, Ari VanderWalde1, Jennifer Gansert1, Robert S Coffin1.   

Abstract

PURPOSE: Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients with unresected stage IIIB to IV melanoma in a randomized open-label phase III trial. PATIENTS AND METHODS: Patients with injectable melanoma that was not surgically resectable were randomly assigned at a two-to-one ratio to intralesional T-VEC or subcutaneous GM-CSF. The primary end point was durable response rate (DRR; objective response lasting continuously ≥ 6 months) per independent assessment. Key secondary end points included overall survival (OS) and overall response rate.
RESULTS: Among 436 patients randomly assigned, DRR was significantly higher with T-VEC (16.3%; 95% CI, 12.1% to 20.5%) than GM-CSF (2.1%; 95% CI, 0% to 4.5%]; odds ratio, 8.9; P < .001). Overall response rate was also higher in the T-VEC arm (26.4%; 95% CI, 21.4% to 31.5% v 5.7%; 95% CI, 1.9% to 9.5%). Median OS was 23.3 months (95% CI, 19.5 to 29.6 months) with T-VEC and 18.9 months (95% CI, 16.0 to 23.7 months) with GM-CSF (hazard ratio, 0.79; 95% CI, 0.62 to 1.00; P = .051). T-VEC efficacy was most pronounced in patients with stage IIIB, IIIC, or IVM1a disease and in patients with treatment-naive disease. The most common adverse events (AEs) with T-VEC were fatigue, chills, and pyrexia. The only grade 3 or 4 AE occurring in ≥ 2% of T-VEC-treated patients was cellulitis (2.1%). No fatal treatment-related AEs occurred.
CONCLUSION: T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial. T-VEC was well tolerated and resulted in a higher DRR (P < .001) and longer median OS (P = .051), particularly in untreated patients or those with stage IIIB, IIIC, or IVM1a disease. T-VEC represents a novel potential therapy for patients with metastatic melanoma.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26014293     DOI: 10.1200/JCO.2014.58.3377

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  837 in total

1.  Retargeted oncolytic viruses provoke tumor-directed T-cell responses.

Authors:  Arnold Kloos; Norman Woller; Rita Gerardy-Schahn; Florian Kühnel
Journal:  Oncoimmunology       Date:  2015-08-20       Impact factor: 8.110

2.  Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes.

Authors:  Nathan Andrew Rohner; Susan Napier Thomas
Journal:  J Control Release       Date:  2015-12-23       Impact factor: 9.776

3.  The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells.

Authors:  Hong-Sheng Dai; Nathaniel Griffin; Chelsea Bolyard; Hsiaoyin Charlene Mao; Jianying Zhang; Timothy P Cripe; Tadahiro Suenaga; Hisashi Arase; Ichiro Nakano; E A Chiocca; Balveen Kaur; Jianhua Yu; Michael A Caligiuri
Journal:  Immunity       Date:  2017-07-18       Impact factor: 31.745

Review 4.  Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.

Authors:  Aric Colunga; Thomas Pulliam; Paul Nghiem
Journal:  Clin Cancer Res       Date:  2017-12-07       Impact factor: 12.531

5.  The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model.

Authors:  Rui Tanaka; Fumi Goshima; Shinichi Esaki; Yoshitaka Sato; Takayuki Murata; Yukihiro Nishiyama; Daisuke Watanabe; Hiroshi Kimura
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

6.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

7.  Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model.

Authors:  Lianwen Zhang; Michael B Steele; Nathan Jenks; Jacquelyn Grell; Marshall Behrens; Rebecca Nace; Shruthi Naik; Mark J Federspiel; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2016-09-26       Impact factor: 11.454

8.  Speciation of Phenanthriplatin and Its Analogs in the Core of Tobacco Mosaic Virus.

Authors:  Amit A Vernekar; Gilles Berger; Anna E Czapar; Frank A Veliz; David I Wang; Nicole F Steinmetz; Stephen J Lippard
Journal:  J Am Chem Soc       Date:  2018-03-19       Impact factor: 15.419

9.  Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.

Authors:  Hong Jiang; Yisel Rivera-Molina; Candelaria Gomez-Manzano; Karen Clise-Dwyer; Laura Bover; Luis M Vence; Ying Yuan; Frederick F Lang; Carlo Toniatti; Mohammad B Hossain; Juan Fueyo
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

Review 10.  Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities.

Authors:  Ravi B Patel; Claire C Baniel; Raghava N Sriramaneni; Kristin Bradley; Stephanie Markovina; Zachary S Morris
Journal:  Brachytherapy       Date:  2018-08-02       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.